Pharmaceutical Executive-09-01-2013

Pharmaceutical Executive

What it takes for promotional review teams to function at their best and avoid costly mistakes.

Pharmaceutical Executive

What does a challenger brand need to do?

Pharmaceutical Executive
Features

September 01, 2013

The Sunshine Act's Open Payments spending disclosure program is now live. The government's lead compliance officer explains how it will work.

Pharmaceutical Executive
Column

September 01, 2013

Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share.

Pharmaceutical Executive

Are electronic health records a viable channel for engagement? Ben Comer reports.

Pharmaceutical Executive
From the Editor

September 01, 2013

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.

Pharmaceutical Executive
Column

September 01, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

Pharmaceutical Executive

With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided.

Pharmaceutical Executive
Country Report

September 01, 2013

Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's healthcare system has turned "improving quality" into the top priority of the government of Indonesia. Better quality of care has become especially important as the fourth most populated country in the world moves forward with its plans to achieve universal healthcare coverage.

Pharmaceutical Executive
Features

September 01, 2013

Normal service will be resumed as soon as possible.

Pharmaceutical Executive

By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.